These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 9133074)
21. Current issues in dendritic cell cancer immunotherapy. López JA; Hart DN Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565 [TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625 [TBL] [Abstract][Full Text] [Related]
23. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Hino M; Kohchi C; Nishizawa T; Yoshida A; Nakata K; Inagawa H; Hori H; Makino K; Terada H; Soma G Anticancer Res; 2005; 25(6A):3747-54. PubMed ID: 16302735 [TBL] [Abstract][Full Text] [Related]
24. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Li J; Hu P; Khawli LA; Epstein AL Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000 [TBL] [Abstract][Full Text] [Related]
28. Functions of natural killer cells. Vivier E; Tomasello E; Baratin M; Walzer T; Ugolini S Nat Immunol; 2008 May; 9(5):503-10. PubMed ID: 18425107 [TBL] [Abstract][Full Text] [Related]
29. Overview: immunotherapy for cancer--is it time for the kitchen sink? Davis TA Curr Opin Investig Drugs; 2002 Jan; 3(1):130-1. PubMed ID: 12054063 [No Abstract] [Full Text] [Related]
30. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Schreiber K; Rowley DA; Riethmüller G; Schreiber H Hematol Oncol Clin North Am; 2006 Jun; 20(3):567-84. PubMed ID: 16762725 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant histamine in cancer immunotherapy. Hellstrand K; Hansson M; Hermodsson S Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269 [TBL] [Abstract][Full Text] [Related]
33. [The use of autovaccines prepared on a base of microbial synthesis products for the stimulation of body antitumor resistance]. Shalimov SA; Potebnia GP; Keĭsevich LV; Litvinenko AA; Lisovenko GS; Koval'chuk AV; Kot LN; Shumilina VV Klin Khir (1962); 1994; (5):69-73. PubMed ID: 7807914 [No Abstract] [Full Text] [Related]
34. The anti-idiotype vaccines for immunotherapy. Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733 [TBL] [Abstract][Full Text] [Related]
35. The evolution of antibodies into versatile tumor-targeting agents. Lin MZ; Teitell MA; Schiller GJ Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537 [TBL] [Abstract][Full Text] [Related]